Kedhbs

Human Hepatitis B Immunoglobulin, the active ingredient in Kedhbs, is an immunoglobulin presented as a sterile injectable for intramuscular use. It provides passive immunity to prevent hepatitis B infection after exposure. GNH USA supplies Kedhbs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kedhbs is an immunoglobulin that provides passive immunity against hepatitis B virus.

- Post‑exposure prophylaxis: prevents hepatitis B infection after known or suspected exposure. - Prevention after perinatal exposure: administered to newborns of hepatitis B‑positive mothers to reduce mother‑to‑child transmission. - Immunoprophylaxis for non‑immune individuals: provides immediate protection to persons lacking hepatitis B antibodies who are at risk of infection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the intramuscular site. - Redness or swelling: localized erythema or edema at the injection area. - Fever: transient low‑grade temperature elevation. - Headache: mild headache occurring within hours after administration. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Serum sickness-like reaction: fever, rash, arthralgia occurring days after dosing. - Aseptic meningitis: rare inflammation of the meninges without infection. - Thrombocytopenia: low platelet count leading to bleeding risk. - Hemolysis: destruction of red blood cells causing anemia.

Before administering Kedhbs, consider the following precautions: - Assess hepatitis B serology: confirm lack of protective antibodies before use. - Screen for hypersensitivity: avoid in patients with known allergy to human immunoglobulins. - Use with caution in immunocompromised patients: monitor for altered efficacy. - Avoid in individuals with IgA deficiency and anti‑IgA antibodies: risk of severe reactions. - Monitor for signs of infection: observe for fever or systemic symptoms post‑injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hepatitis B Immunoglobulin may interact with other agents as follows:

Major Interactions (Avoid): - Live vaccines: concurrent administration may reduce vaccine efficacy. - Serologic testing: may interfere with hepatitis B surface antigen assays, leading to false‑positive results.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of bleeding at injection site. - Immunosuppressants: potential alteration of passive immunity duration. - Other immunoglobulin products: cumulative antibody load may increase risk of adverse reactions.